Healthcare provider profile · identity verified

Shereen Aysheh

Nurse Practitioner · OCALA, FL · NPI 1053085621

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Potassium Chloride	Potassium Chloride	183	32
Atorvastatin Calcium	Atorvastatin Calcium	140	24
Furosemide	Furosemide	130	32
Amlodipine Besylate	Amlodipine Besylate	125	20
Levothyroxine Sodium	Levothyroxine Sodium	123	23
Gabapentin	Gabapentin	107	27
Trazodone Hcl	Trazodone Hcl	106	24
Omeprazole	Omeprazole	95	19
Buspirone Hcl	Buspirone Hcl	91	13
Eliquis	Apixaban	88	13
Metoprolol Tartrate	Metoprolol Tartrate	85	18
Losartan Potassium	Losartan Potassium	74	12
Metformin Hcl	Metformin Hcl	70	11
Spironolactone	Spironolactone	70	13
Quetiapine Fumarate	Quetiapine Fumarate	66	14
Tamsulosin Hcl	Tamsulosin Hcl	65	13
Lisinopril	Lisinopril	64	11
Sertraline Hcl	Sertraline Hcl	58	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	56	13
Escitalopram Oxalate	Escitalopram Oxalate	51	11
Metoprolol Succinate	Metoprolol Succinate	50	11
Metolazone	Metolazone	46	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	45	suppressed
Diclofenac Sodium	Diclofenac Sodium	43	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	37	30
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Ibuprofen	Ibuprofen	35	14
Famotidine	Famotidine	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Donepezil Hcl	Donepezil Hcl	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	32	suppressed
Prednisone	Prednisone	30	19
Albuterol Sulfate Hfa	Albuterol Sulfate	28	suppressed
Azithromycin	Azithromycin	28	23
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Memantine Hcl	Memantine Hcl	28	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	20
Glipizide	Glipizide	27	suppressed
Meclizine Hcl	Meclizine Hcl	27	suppressed
Amiodarone Hcl	Amiodarone Hcl	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	19
Ciprofloxacin Hcl	Ciprofloxacin Hcl	24	19
Rosuvastatin Calcium	Rosuvastatin Calcium	24	suppressed
Simvastatin	Simvastatin	24	suppressed
Glimepiride	Glimepiride	23	suppressed
Latanoprost	Latanoprost	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Diltiazem Hcl	Diltiazem Hcl	20	suppressed
Lactulose	Lactulose	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Celecoxib	Celecoxib	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Sotalol	Sotalol Hcl	17	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Fluorometholone	Fluorometholone	15	suppressed
Nystatin	Nystatin	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Finasteride	Finasteride	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Ramipril	Ramipril	12	suppressed
Galantamine Hbr	Galantamine Hbr	11	suppressed
Humalog	Insulin Lispro	11	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Trulicity	Dulaglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error